OGEN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Oragenics Inc. (OGEN) is not a strong buy for a beginner, long-term investor at this time. While the company has shown progress in its clinical trials, the financial performance is weak, and there are no significant trading signals or valuation data to support a strong entry point. The pre-market price increase and technical indicators suggest short-term momentum, but this does not align with a long-term investment strategy.
The MACD is positive and expanding, indicating bullish momentum. RSI is neutral at 64.925, and moving averages are converging, suggesting no clear trend. The stock is trading near its R1 resistance level of 0.682, with a pre-market price of 0.7091, which is above R1 but close to R2 at 0.723. This indicates limited upside potential in the short term.
The company has initiated a Phase 2a trial for ONP-002, a candidate for treating concussions, marking a significant step forward in addressing an urgent medical need.
Weak financial performance in the latest quarter, with a significant drop in net income (-31.72% YoY) and EPS (-93.59% YoY). Additionally, there are no significant insider or hedge fund trading trends, and no recent congress trading data.
In 2025/Q4, revenue remained at 0 with no growth. Net income dropped significantly to -$2,286,870 (-31.72% YoY), and EPS fell to -0.54 (-93.59% YoY). Gross margin remains at 0, indicating no profitability.
No analyst rating or price target data is available for OGEN.
